Cite
HARVARD Citation
Jamal, R. et al. (2016). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Journal for immunotherapy of cancer. 4 (1), p. . [Online].